Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas

Category Primary study
JournalJournal of Clinical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: bc2c036f9c87f6828af5973d4c6cfd0eca167c80
First added on: Feb 19, 2025